Puberty Blockers and Cross-sex Hormones
Thursday, 22 October 2026
Contributions
Question for Short Debate
Asked by
Baroness Deech
To ask His Majesty’s Government at what age they consider it appropriate for an individual to be able to consent to the administration of puberty blockers and cross-sex hormones.
Baroness Deech (CB)
My Lords, I declare an interest as a former chair of the Human Fertilisation and Embryology Authority, where I witnessed the pain of those whose fertility was impaired. This question is not about the transgender identity of adults. Anyone who turns it into a debate about that is distracting from the issue. It is about very young children being deemed capable of assenting to medical interventions whose effects and risks they cannot understand. Across UK law, the age at which a young person is deemed capable of consenting to significant activities is far from uniform. At 16, one may consent to sexual activity, leave home, work and join the Armed Forces, with parental permission. We just listened to a very solid debate about the harm that could be caused to young children under that age by social media. At 17, one may drive. At 18, one may serve on a jury, vote—at the moment—buy alcohol and enter contracts. This reflects the law’s recognition that maturity develops unevenly, but it also exposes a striking inconsistency. We prohibit young people making irreversible decisions in almost every other domain until adulthood, while in the PATHWAYS trial of puberty blockers we will permit exceptionally young children to assent to powerful drugs whose effects they cannot grasp. How do the Government reconcile the exceptionally young ages for this trial? Parliament frequently makes decisions about medical limits—screening, assisted dying, affordability of new drugs, abortion regulation and so on—so it is no answer to say to leave it to the clinicians. I suggest that a child does not have the legal competence to give effective consent to life-changing medical interventions. The evidence base shows how great the risks are to an individual child, who should not be used as a test case for future general medical advances. Views on this trial have fluctuated and it is reported that certain people opposed to it were removed from involvement. Following consultation this year, NHS England confirmed that MAF hormones will no longer be routinely commissioned or prescribed for under-18s. This aligns with the indefinite 2024 ban on puberty blockers, which will be reviewed in 2027. I urge the Government not to reduce age limits. Even 16 is safer than younger ages because more physical development has occurred. The PATHWAYS trial is an outlier; it allows enrolment of children as young as 11 and 12. The central issue is consent. We have something in law called Gillick competence, which means that under-16s may consent if they demonstrate sufficient maturity and understanding. The Gillick case arose from a case about contraceptive advice, not irreversible medical interventions. The key question is: can a prepubescent child comprehend the long-term effects of puberty blockers or hormones? Does the Minister really believe that meaningful understanding is possible at that age? The findings from the Cass review and others show risks: bone health deficits; fertility, pregnancy and offspring impacts; sexual function impairment; effects on brain maturation; and cardiovascular and haematological risks. The additional safeguards that were added to PATHWAYS acknowledge these risks; they do not remove the irreversibility. We all have the greatest respect for the noble Baroness, Lady Cass, whose pioneering work raised the dangers of puberty blockers. It will be argued in this debate that there are special reasons for allowing the trial at such a young age, which she has put forward. One is to turn children away from illegally accessing these drugs, but it is very unlikely that this relatively small trial with selected children will lead them to believe that they can access these drugs legally. Possible harm reduction is not an aim of the trial and there will be no evidence that this is the outcome. Another argument is the plight of distressed children living in stealth, but unless they stay at home and out of school, a child who presents as a member of the other gender or who has delayed puberty is likely to be highly visible at school, one way or the other, and still stressed. Moreover, there is no comparative trial, save a delay of 12 months. We will not find out whether children who are denied or given these drugs are in better shape in, say, five or 10 years’ time. Only retrospective data analysis can tell us that. A useful comparator would be holistic psychosocial support. Rather than a trial, there should be follow-ups on patients who have already taken these drugs, here and abroad, and a review of the regulation and the robustness of diagnosis. May we be told how clinicians will test the child’s understanding of what may happen? How will they distinguish the parents’ understandable wish to relieve the child’s distress, which is a different concept from the child’s own assent? If this trial goes ahead—we do not know whether it has started—will the Government undertake never to permit another trial on any children aged under 18, or even 16? Will there be sufficient data collection, including on withdrawal and any ill effects? May we be assured that parents will not be punished or pressured into giving their consent? Why can this trial not be replaced by the tracking of past use of puberty blockers? The Gender Recognition (Disclosure of Information) (England) Order came into force in March. It will allow the disclosure of formerly protected information and facilitate a retrospective observational study tracking the health outcomes of roughly 9,000 adults who were referred, as children, to the former Gender Identity Development Service at the Tavistock and Portman NHS Foundation Trust. Fortunately, the NHS has now moved youth gender services away from medical intervention and towards holistic psychological and psychosocial support, in line with the Cass review. I hope the Minister will affirm that this is the future model and first resort for all young people presenting with gender dysphoria. There is also concern about overdiagnosis, given the sharp rise in recent years and the parallels with other mental health diagnostic trends. A study from the University of York showed that diagnoses of gender dysphoria had increased from one in 60,000 teenagers in 2011 to one in 1,200 10 years later—a rise too astonishing to be taken at face value. My final question: bearing in mind the deluge of emails I have received from members of the public, what assessment have the Government made of the appropriate age at which a young person can understand and consent to puberty blockers and cross-sex hormones?
Baroness in Waiting/Government Whip (Baroness Hyde of Bemerton) (Lab)
My Lords, before we continue with this Question for Short Debate, I remind all noble Lords that the advisory speaking time is five minutes. I urge noble Lords to keep within that limit so that the debate can conclude within the time allowed without cutting short the Minister’s remarks, which I know noble Lords will be very keen to hear, at its conclusion.
Lord Winston (Lab)
My Lords, it is always a pleasure to speak after the noble Baroness, Lady Deech, even when I disagree with her. Unfortunately, that happens all the time, much to my embarrassment. Like her, I greatly welcome the noble Baroness, Lady Cass, to speak on this subject, on which she is so expert. Unlike the noble Baroness, Lady Deech, I am afraid that I am not prepared to say that we do not discuss anything other than gender dysphoria. It is not just the trials of the drugs; we also have to understand that there are some issues here that are very common to in vitro fertilisation—the most common being that, with in vitro fertilisation, we are increasingly treating patients without any diagnosis of the cause of the infertility. That may be the problem with a trial such as this, and I am sure that the noble Baroness, Lady Cass, will identify and address that problem, because it is a real issue. I suggest that some of the research we are not doing is worth doing but, unfortunately, it is not getting funded. One of the areas that I have already discussed with my noble friend the Minister is epigenetics. Interestingly, there are certain reasons for believing that epigenetics might be very relevant to this situation. I first heard of this when I was lecturing in Melbourne, Australia, in the late 1970s—not that it was called epigenetics then. I came across a consultant who said he had seen so many patients—it was common—who requested gender change or had some form of dysphoria. He said that when he went through the medical records of the obstetric cases, he was interested to find some anomalies. In some cases, patients had been exposed to unusual stress or other issues that might have been related to the environment the mother was in. I have no idea whether that research went on; the consultant is now dead, but I would have loved to have seen it. It was certainly not until about 1999, when Lars Bygren published his first paper on the key issue of what happens to children as they grow up following different exposures to different environments, that we suddenly woke up. These things were often sex-linked, by the way, which is quite interesting. It turns out that some of the issues here are true in transgender as well. That is also a sex-linked issue. Of course, many of these children may have some suggestions of autism or certainly some form of difference or disorder—I do not want to call it mental ill health—that we would not accept as being quite usual: on a spectrum, as is often said. That is a reasonable way of looking at it. I need to explain epigenetics to make this understood. I want noble Lords to consider this question. Let us suppose that “My coat is grey” is written in the alphabet of the DNA. That could be expressed in two ways: “My coat is gray” or “My coat is grey”—the difference between them is not important. It works both ways. But a mutation would be if that “c” was changed into a “g”: “My goat is grey”. I am not suggesting that this is a mutation, but there are other things that we now know affect the DNA and how it works. For example, if you put “My coat is grey” in quotation marks, that changes it. So it is not the actual letters of the DNA but the environment in which it is written. If you put an exclamation mark or a question mark after that sentence, you end up with the possibility of the meaning being totally changed. There is a possibility that that is happening increasingly. We have animal evidence that is very strong, and we also have evidence from Canada—McGill and Toronto—that shows that this might be true in humans and could be to some extent heritable. This is not, of course, gender dysphoria; it is troubles of this sort generally. I do not have an answer to the Question being asked in this debate, but we need to consider how, and whether, we can use drugs for different causes that are not, in fact, a medical condition. The problem is how we define transgender and how we deal with that. That is why I am so pleased that the noble Baroness, Lady Cass, is here to answer those questions, because I think we will want to discuss that at great length. We must have trials if we are going to get anywhere. The problem is: how do we do this without damaging children? I agree completely with the noble Baroness, Lady Deech, that we must do follow-up with transgender. We have not done it at all, and it has to happen.
Baroness Buscombe (Con)
My Lords, the Government’s first duty is to protect their citizens from harm. This Government are failing in that duty of care for our children. Two years ago, during a debate on the use of puberty blockers, I reminded the House that I had represented Her Majesty’s Opposition through the passage of the Gender Recognition Act. That was 23 years ago. It had been scrutinised in draft form by the Joint Committee on Human Rights and was steered through your Lordships’ House by the then Minister, the noble Lord, Lord Adonis. I had been reassured repeatedly that gender dysphoria affected a tiny number of people in the UK—5,000 at the very most—and that there was no indication, research or medical evidence that this cohort would grow. Some 23 years on, we are facing the most appalling situation whereby this Government think it is okay to use young children in random clinical trials—experiments—that may and probably will have a lasting and possibly irreversible and seriously harmful physical and/or mental effect upon some or all of those children. There is no scientific evidence to back this experiment up. I have huge respect for the Minister, who is in a very difficult position. I have considered with care her response and other responses to the recent Oral Question from the noble Baroness, Lady Deech, in your Lordships’ House on 25 June 2026. I find them shocking and revealing. In her initial response, the Minister stated, with regard to the PATHWAYS trial: “Eligibility is tightly controlled; it requires parental consent, a minimum two-year gender incongruence diagnosis, psychosocial support, and NHS and multidisciplinary team approval, as well as participant understanding of the risks and benefits, physical and mental stability, and compliance with safeguarding requirements ”.—[ Official Report , 25/6/26; col. 754.] With respect, this is verbal nonsense designed to mask the reality. Where and what are the safeguards that should govern any administration of these drugs to children? Does this not make a mockery of safeguarding? Seriously, on 11 and 12 year-old participants understanding the risks, how can a prepubescent child comprehend the long-term effects of puberty blockers or hormones? What about legal competence? There is also, in the answers to Question from the noble Baroness, Lady Deech, a clear message from the Government Benches that this is “not political”. Why is that? This indicates to me that the Government are keen to ensure that this experimenting with young children’s lives is seen as a cross-party exercise—oh, and that includes the bishops. So, when it goes wrong, we can all share the blame. It is wrong—wrong. In addition, I was shocked to read the contribution from the noble Lord, Lord Cashman, that “the only thing that matters in this instance is the right of the child to the best and most appropriate treatment”. Given the possible effects of these drugs, do we defer to the right of a child aged 11 or 12? That is madness. The noble Lord, Lord Scriven, suggested that “getting an evidence-gathering trial under way would be an effective way to protect them from the dangers of these unregulated and unmonitored markets ”.—[ Official Report , 25/6/26; col. 755-6.] So, just because this country is now almost entirely lawless, with scant enforcement, let us experiment on our children, rather than tackle the unregulated—that is, illegal—drugs market. The right reverend Prelate the Bishop of Manchester said that, in effect, experimenting with our children is a handy way of removing the culture wars; it was well meant, I am sure, but all this suggests to me is that it helps to explain the current state of the Church of England. Further, I put it to the Minister—whom, I repeat, I really do respect—that when, in one of her answers, she said that it is “important to have a cool head ”,—[ Official Report , 25/6/26; cols. 756.] she revealed that she is just as apprehensive as the many thousands of others who cannot understand the mindset of those pushing this. I turn briefly to those selected for the so-called trials. Can the Minister tell us, given the Government’s obsession with diversity, equality and inclusion, whether participants include children from different ethnic and religious groups—plus maybe one or two who are directly related to members of this Government? How does it go? The evil that men do lives after them. I shall end this as I did the last time I spoke on the subject. As a mother, a grandmother and a Peer, I urge the Government to think again and stop this nightmare.
Baroness Cass (CB)
My Lords, I declare my interests: I am the noble Baroness, Lady Cass, of the Cass review and an independent advisor to DHSC. As my noble friend said, the age at which under-16s can consent to medical interventions is determined by Gillick competence. Specifically in relation to puberty blockers, this issue has been tested through the courts through Bell v Tavistock. The original judgment was overturned on appeal because the court held that it was wrong to try to establish age-based criteria for competence, which must instead be assessed case by case in accordance with the Gillick principles. As noble Lords have already heard, because this is part of an approved research trial, children cannot consent anyway—they assent, and parents consent. So, with all due respect to the Minister, the only basis on which His Majesty’s Government can take a view on the question would be if they wanted to challenge the legal judgment or seek to change the law. As noble Lords have also heard, the routine commissioning of masculinising and feminising hormones is currently suspended. That is probably as far as one can go on the core question itself, but I understand the strength of feeling in the House, so I will say a little about children’s and young people’s gender services and how they are operating. The service currently includes five of the UK’s specialist children’s hospitals, and more centres are opening soon. It is staffed by some of the country’s most experienced professionals in children’s physical and mental health, and the chair of the network is a past president of RCPCH. To be absolutely clear, this is not a service driven by ideology. About 1,600 children and young people have been seen. They have a very wide range of problems, including depression, separation anxiety, social phobia, eating disorders and neurodiversity, and many of them have quite striking physical symptoms including pain, impaired mobility and functional impairment, which impacts on their ability to attend school, interact with peers and engage in normal physical activities. For some families there have been stresses such as domestic violence, parental mental health problems or parental death. A sizable minority of the patients are open to the safeguarding team—for example, because they suffered physical or sexual abuse, online grooming or exploitation, or because they are taking a range of unregulated medicines and hormones. So, the clinical team are providing a very wide range of therapeutic interventions aimed at improving physical and mental health and functional well-being. Sometimes, just addressing general health and nutrition and getting young people out of their bedroom and back into school to engage with peers is all that is needed for their gender distress to largely resolve and for them to re-engage with typical life, development and experience. I should say that we are following up all those children who do not get any medical pathway—or as many as will agree to consent—because one of the things I could not find out during my review, as they did not have the data, is what happened to the children and young people who did not go on a hormone pathway. At this point, fewer than 20 patients out of the 1,600 are even in the early stages of being considered for enrolment in the puberty blocker trial. As I reported previously, they are typically young people who have been socially transitioned since early childhood, and after 18 months of therapy, they still have absolutely no sense or concept of living in their biological gender. Decisions are taken after an extensive assessment and thorough multidisciplinary review, guided by considerations of the young person’s best interests. In other words, the clinicians have to feel that the risks of not enrolling them in the trial will outweigh the risks of enrolling them. In response to my noble friend’s remarks, we do not know of any definite irreversible effects of puberty blockers at this time; that is the whole point of the trial. These children are going to be extremely tightly monitored. The commitment is that they will be allowed to be on them for only two years in the first instance, with no automatic assumption that they will progress to masculinising or feminising hormones without further discussion and a further detailed assessment. The other commitment is that all the time they are on the puberty blockers, they are locked into two years’ further ongoing therapy within the service. For me, that has to be better than going out and getting some testosterone at the gym instead. The combined expertise in child health, mental health, safeguarding, clinical ethics and best interest decision-making within these specialist teams far exceeds that available to either House. For that reason, I have full confidence in their clinical judgments. I apologise to the noble Lord, Lord Winston, that I do not have the answers on epigenetics.
Lord Frost (Non-Afl)
My Lords, it is a pleasure to follow the noble Baroness, Lady Cass, on any subject, but particularly this one. I am grateful to the noble Baroness, Lady Deech, for securing this very important debate. I have not spoken much about this subject in public, but I have followed it closely; I feel strongly about it. I wanted to speak today because I simply fail to understand the logic behind what is going on and what we are allowing to proceed. I support what the Government have done so far on this general issue—the bans and the indefinite pauses on puberty blockers and cross-sex hormones. The Government deserve credit for this, particularly given the strongly held opposition from a narrow group of their own supporters on this subject. However, what I cannot quite follow—I have learned that many other people cannot follow it either—is what is happening now. The Government have judged these drugs too uncertain to give children in the ordinary way of things, but are now prepared to support giving them to 11 and 12 year-olds as an experiment. We know that the MRHA, as a regulator, had misgivings about this and suggested a minimum age of 14—still too low, in my view—but somehow, it has been persuaded to change its mind and think that 11 or 12 is okay. It is not clear entirely why; perhaps the Minister could shed some light on that. One must ask why this trial is necessary at all. As far as I can see, the only reason one might want to do it is to learn whether we might one day be able to administer such medicines to children who feel gender dysphoria; of course, we already use them in other extremely limited circumstances. If we do not ever wish to do that, why would we want the trial? I recognise that others may not share my view, but personally, because of my own convictions about the nature of reality and sexual difference, I cannot imagine circumstances in which we would ever want to do this. The view that we might rests on the much-disputed premise that a child can have a gender at odds with his or her sex, and that if so, it is the body rather than the beliefs should change. I am afraid I simply do not accept that. I know others will, but I do not. By the way, in passing, I worry that if the Government’s conversion practices Bill ever made it into law, what I have just said would become quite a risky thing to say in quite a lot of circumstances. Gender dysphoria clearly is a real thing, and children who suffer from it deserve all kinds of psychological and social support—the best we can possibly give. But by crediting the belief that in certain circumstances the body should change to reflect the psychology, we surely make dealing with it harder not easier, because that appears to offer a way out. I do not accept the logic behind the trial at all. I just do not understand it. As I have said, I recognise that others may take a different view on the nature of gender and sex differentiation. We live in a free society, of course—but it is a free society for adults, and we have a duty to protect children. In the previous debate we heard the Government saying they were banning sexualised chatbots for children under 18, presumably because they think children under 18 cannot deal with that sort of content. Surely, therefore, we must protect children from irreversible medical treatment, decided on at an age at which no reasonable person would think they could reasonably consent, even in a trial. I do not see how we can, in conscience, proceed with such a trial involving 11 year-olds. I experienced some of the Covid pandemic from the inside of government, more as an observer than a participant. I am afraid I learned from that period that sometimes the cleverest scientists and the most highly respected medical authorities could not see the wood for the trees, and ended up supporting things that were, I think, indefensible. We need to stick to principles sometimes, and one of my principles on this is that it is wrong to administer irreversible treatments to 11 and 12 year-olds. To be honest, I find it shocking and disgraceful that we can do it. It should be opposed in every way possible.
Baroness Murphy (CB)
My Lords, I approach this topic from the point of view of someone who worked for two years, when I was a trainee psychiatrist, in a transsexual clinic for adults at University College Hospital. In those days—I am going back 45 years—men and women came to seek help usually as confirmed transsexuals. In those days it was mostly men wishing to be women; there is a slight reverse nowadays in the desire to change. They had received no help of any kind from childhood. Very muscular men with large Adam’s apples and deep voices struggled to manage in society, or went abroad to seek surgical help to transform themselves into a better facsimile of a woman—with unpredictable consequences and sometimes horrendous outcomes. Like many people, and I suspect I was in those days in the same school of approach as the noble Lord, Lord Frost, to these problems—I was very young—I thought to myself, “Well, these people are deluded. Why on earth are we colluding with this stuff?”, but I gradually came to the conclusion that my task as a psychiatrist was to try to help all individuals feel more at ease in their own skin and live the life that helped them to feel more content and at one with society, and for lifelong transsexuals that help must be given before puberty. As we have heard from my noble friend Lady Cass, those who are chosen for these trials and treatment have usually been feeling this way since they were aged three or four, when they thought back to when their gender identity was formed. How and when should medical intervention be proffered, therefore, if it is to be given before puberty? If you do not, the outcome can be quite horrendous, in terms of lifetime achievements for these people. The review by my noble friend Lady Cass of the special problems posed by gender dysphoria, and it is now two years since it was published, has been enormously helpful and influential in ensuring that unregulated prescriptions ceased and that prescription puberty blockers and other medications only take part within a carefully regulated research framework, with the aim of establishing better guidance. I remind noble Lord that we do trials for drugs on children in very many walks of life, often in quite serious life-threatening disorders and others, when we feel it will be helpful. We do it with the children’s assent when it has been explained, but with parental consent as well, and it is under those terms the proposals for research are handled at the moment. I pay tribute to the determination of the noble friend Lady Cass to stick to her guns in the face of much upset in the transactivist world on one hand, and on the other those who do not wish to see any interventions before an adolescent can fully understand and make their own decisions. My view is that she got the balance right. These children need a holistic approach to treatment, as we have already pressed, and strong up-to-date medical evidence. However, they often have lots of other problems that need to be looked at. If you do look at those problems in detail, you will end up with a very small group of people who need this kind of intervention. We know that the children and their parents will get drugs from unregulated sources if we do not make progress in establishing appropriate routes, so I support the PATHWAYS research programme because it has such a broad look at all aspects of the impact of these drugs. It also checks on bone density, brain function, fertility and the longer-term outcomes. We know that very many of these people will eventually turn out to be homosexual as men and women. Very few will remain transsexual all their lives, but it is those on whom we need to concentrate. Many of these children have struggled for a long time to come up to speed with their problems, but they cannot do it without more help. To leave them without any sort of support for their gender dysphoria, when you know that they are confirmed transsexuals, does suggest that you are turning them away and saying, “No, you are deluded. We won’t help”. I do not think we can do that as a caring society. We need to recognise and support them in what they wish to do.
Baroness Meyer (Con)
I thank the noble Baroness, Lady Deech, for tabling this important debate that concerns children and the age at which those trials should be undertaken. How can an 11 year-old child understand the consequences of interrupting their puberty, particularly when adults still lack reliable evidence about the long-term consequences? As we know, the Cass review concluded that the evidence supporting puberty blockers was sorely lacking and recommended their use only within a formal clinical trial. NHS England subsequently ended their routine use. As the noble Lord, Lord Frost, mentioned, in February, the PATHWAYS trial was paused following serious concern from the MHRA, including its recommendation that eligibility should be restricted to those aged 14 and over. Yet the revised protocol permits children as young as 11 to receive puberty blockers. Can the Minister explain what new evidence justified lowering the minimum age from 14 to 11 and 12 and what independent scrutiny preceded that decision? It is particularly troubling to note that the original committee reportedly met only three times, with just three members attending its final meeting. The need for better evidence cannot in itself justify exposing children to treatments, the long-term effects of which are uncertain and may be irreversible. Rather than using children as guinea pigs, should we not first examine the existing evidence of those who regretted their treatment, including Keira Bell and Sinead Watson? Eleven year-old girls and 12 year-old boys are barely out of primary school. We recognise that their capacity to assess long-term consequences is still developing. Under-18s cannot purchase alcohol or marry, even with parental consent. I am also concerned about children in care and those with autism or other mental difficulties. Yet children in care are eligible for the trial. Who will independently represent their interests? Children under 16 cannot give legal consent to participate in this medical trial; a parent or legal representative must consent on their behalf. But parents faced with a desperately unhappy child may feel enormous pressure to act. How will the trial ensure that consent is genuinely informed and each child’s understanding is properly assessed? Has recruitment begun? Will every participant receive thorough psychological assessment and continuing support? Above all, how do the Government reconcile the participation of children so young with their duty to protect them from harm? Is there not a danger that the state’s pursuit of scientific research is taking precedence over its duty to protect children? Are we really prepared to place 220 children in a trial without being able to answer the most basic question: at what age can a child understand and consent to a medical intervention that may shape the rest of their life? It was mentioned that children participate in clinical trials, but these are often children who have cancer, where the question of consent is quite different from participating in an experiment. I therefore ask the Minister directly: why 11 and 12 year-olds? What evidence justifies those ages, and how can the Government be confident that these children are being protected rather than exposed to risks that they are too young to understand? Their welfare must come first—not simply during the trial but throughout their childhood and their adult life.
Baroness Barker (LD)
My Lords, this debate is happening in the context of two very well-funded campaigns. There are two groups of people: one does not believe that trans people exist; another believes that trans people might exist, but that all of them—every one of them—pose such a threat and danger to the rest of us that they have to be segregated. The thing on which those two different campaign groups unite is a constant campaigning to make the lives of trans people impossible in a series of different, small actions. We see it every day in our newspapers and on the BBC: different aspects of making life difficult and blaming trans people for everything. There is a third group of people, to which I belong, who believe that trans people are human beings, have the same rights as anybody else and should be treated and judged just as everybody else is. That pertains to healthcare as much as anything else. When I was preparing for the debate, I looked in my inbox and found a very helpful email from the noble Baroness, Lady Cass. Following the attempt by the noble Baroness, Lady Deech, to raise this matter, she circulated a paper to us, which was short but full of detail and answered every single one of the questions that has been put in the debate. It is a shame that people have not bothered to read it. It set out in much more detail than the noble Baroness, Lady Cass, just did all the safeguards that are in this research and why they are there and needed. I have listened to what the noble Baroness, Lady Cass, said and I have come to understand her point of view—I did not necessarily to begin with, but I do now. I echo those who have said that she deserves to be commended for what she is putting in place. It is evidence-based scientific research, not prejudice, ideology or a set of researchers going off on some kind of tangent to experiment on children. It sets out to answer the questions that we do not know the answer to. I do not understand gender dysphoria. I have never experienced it. I know people who have. I hear them describe it and the terrible consequences on their lives. I realise that they have a problem that medicine has tried for a very long time to deal with in kind and ethical ways. The noble Baroness, Lady Cass, is simply part of that ongoing tradition. I very much agree that it is wrong to turn our backs on people who are in some kind of mental distress, although I very much regret the repeated use of terms such as “mental distress” to cover all trans people. I remember that, as a young gay person, that is what they said about me. They were wrong. This campaign is so damaging and regressive. It falls to people in your Lordships’ House to stand up for this visible minority, because they are just the first ones to be in the firing line. The rest of us are going to be there soon, because this is fundamentally a big attack on human rights by very well-funded campaigns, most of which originate in the United States. I simply ask the noble Baroness, Lady Merron: does she agree with the noble Baroness, Lady Cass, that withholding treatment is not a neutral act? The withholding of treatment that might solve a medical problem is not something that we would routinely consider for any other group of people in the whole of medicine. Therefore, does she agree with me that it is important that, having set this process up, the Government shield this research from the never-ending political and ideological attacks on it and that we let the scientists and medics get on with a very important, detailed and serious programme of work, which will help people who some of us in this place clearly do not like, but some of us believe need and require our support?
Baroness Buscombe (Con)
My Lords, I ask the noble Baroness to accept that those of us who have spoken against these trials for young children are not against trans people. If I had another minute to speak, I would have explained that one of my earliest experiences was a deep longing to understand what was happening with somebody who was called James Morris and who became Jan Morris. In previous debates on this, I have spoken of my thorough respect for him and others like him, who have been in a medical, physical and emotional hell until they have gone through a process to change their sex. I admire people like him and others. Will the noble Baroness accept that we are not part of some political campaign—
Baroness Hyde of Bemerton (Lab)
I am going to suggest that we move on to the noble Baroness, Lady Cash. It was not really proper to intervene at that moment.
Baroness Cash (Con)
My Lords, I too am very grateful to the noble Baroness, Lady Deech, for securing this debate. As her debate focuses on the age of consent, there is a limited amount to be added to what has already been said by those who have spoken ahead of me. However, the debate does draw attention to an ongoing medical scandal of our times, which is the consent to drugs around which we have no evidence of safety. The noble Baroness, Lady Cass, for whom I have the highest of regard and esteem, and with whom I have discussed this subject with gratitude on multiple occasions, disagrees with me about the PATHWAYS puberty blockers trial. We agree on almost everything else. I think the nub of the debate lies there. What I am hearing in the Chamber today is real concern about the age of children who are embarking on life-changing and possibly irreversible changes to their physical bodies: to their brain, to their bones, to their IQ and to their fertility. We just do not know whether the changes caused by use of puberty blockers in young people can be reversed. I hope I have read the review—the famous Cass Review —correctly. I hope so because I have read it several times; but when the noble Baroness refers to not withholding treatment, my understanding of that is that she means exploratory treatment, ensuring that the multiple reasons why children present in distress about their gender are fully explored and that they are given the opportunity to have the correct therapies and treatments for any of those issues. There are comorbidities. A disproportionate number with gender distress are autistic, have mental health conditions or are in care. However, left alone, as the Cass review stated, most childhood gender distress resolves. In the largest follow-up study of 139 boys, most desisted, and a high proportion grew up to be gay or bisexual. Puberty blockers can prevent the child from processing their issues and their reasons. In the Tavistock’s own study, children embarked on puberty blockers went on to cross-sex hormones at a rate of 98%, almost the inverse of the resolution that takes place if puberty blockers are not taken. Therefore, we cannot set a safe age because no one has followed up on these young people. I appreciate and acknowledge that that is also something that the noble Baroness, Lady Cass, has highlighted and drawn attention to. We have also seen an independent investigation by Professor Ellis into the WellBN clinic in Brighton, examining 78 children: 51 aged 16 and under given cross-sex hormones; four started at 12, four at 13, and more than two-thirds—53 of 78—had possible neurodevelopmental conditions. Capacity to consent was confirmed in only six cases out of 78; 22 children were prescribed without ever being seen face to face and 36 received prescriptions at their first appointment. That is not a treatment; that is a scandal—23 different prescribers were involved and one child lived more than 480 miles away. The NHS and the GMC were warned from at least 2020, but they failed to act. The investigation is meant to have a second phase to review those children who are now adults, but that phase is on hold, and those young adults matter just as much. That data, the follow-up data, was withheld from the Cass review when it was trying to follow up on the children who had been treated at an earlier stage. The law was changed for that data-linkage study to be provided, and it still has not been. The law needs to compel it to be disclosed so we truly can establish what happens to these young people after these treatments. The Levy review proposes moving more adult prescribing into GP-led services. That is the WellBN model, and it should not happen because we need to understand the scandal of this Wild West of medical treatment without meaningful consent before any further instances can take place, because there will be a cost to the NHS, as in the United States, where legal claims against the clinicians and the hospitals are now being brought. I therefore use this opportunity to urge the Government to commission an independent inquiry into gender-related prescribing in primary care and in adult clinics, with a focus on those under 25.
The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Merron) (Lab)
My Lords, I congratulate the noble Baroness, Lady Deech, on securing this debate today and airing the issues—which clearly need airing—and I thank all noble Lords for their contributions. There is probably only one thing that unites all the contributions, which is concern for the safety and well-being of children and young people. There is, of course, considerable difference of opinion among contributors. I start by making it clear that the government policy on care for children and young people with gender incongruence is underpinned by the absolute need for them to receive safe care based on evidence, which is what will always drive us. That is why we are implementing the Cass review. I am most grateful to the noble Baroness, Lady Cass, not just for conducting the review but for her continued work and indeed for her contribution today. In many ways, she has saved me something of a job by setting out the facts, as she did when she previously wrote to all noble Lords, so I will not repeat a number of those points. We are implementing the Cass review and transforming children and young people’s gender services. These services, including the four new services that are now operating, with plans for provision in every region of England by the end of 2027-28, provide a holistic model of care, with a focus on psychosocial support, which the noble Baroness, Lady Deech, asked about. The service specification for these services is quite clear that medical intervention is not the standard approach to care. If we look back to March 2024, it was then that NHS England issued a clinical policy which set out that puberty-supressing hormones are not available for routine commissioning within the gender services. This followed a number of evidence reviews that did not identify good enough evidence about safety, risks, benefits and outcomes. The Cass Review , which was commissioned under the previous Government, was published in April 2024 and also found that there was insufficient evidence. The then Health Secretary, Victoria Atkins, welcomed the review and committed to implementing its recommendations. There was an introduction of an emergency order restricting the private sale and supply of puberty-suppressing hormones for gender incongruence—I believe the noble Lord, Lord Frost, welcomed that action, as indeed I did, not least because this Government picked that up and extended the restrictions, making them indefinite from January 2025. I remind your Lordships’ House that the decision was upheld in the High Court when it was challenged. The decision in respect of implementing recommendations and the response on puberty-suppressing hormones was taken with great care. It was informed by a wide range of evidence, including a report from the independent Commission on Human Medicines, which indicated that young people with gender incongruence and dysphoria were uniquely being exposed to potential safety risks. I listened closely to all the contributions, but I believe the noble Baroness, Lady Murphy, set out why doing nothing is not a neutral option, which the noble Baroness, Lady Barker, referred to. To put it in my own non-medical language, the issue does not go away by doing nothing. Regarding the PATHWAYS study, which a number of noble Lords have referred to, the Cass review drew attention to how we need better evidence. We must be able to inform clinical decisions with—I shall reuse my words, looking at the noble Baroness, Lady Buscombe—a cool head. I hope that the evidence will inform the decisions made by children and their families. NHS England and DHSC, through the National Institute for Health and Care Research, worked to design and fund a research programme. It includes a regularly updated, systemic review of available research evidence and, I say to the noble Baroness, Lady Deech, a data linkage survey study—not an either/or but both—as well as the PATHWAYS study. The trial has been approved by the Health Research Authority and the MHRA. We are talking about a trial involving a small number of children and young people who are already receiving the support of NHS gender services. The noble Baronesses, Lady Deech and Lady Meyer, raised the PATHWAYS trial entry age. This has been reviewed by the MHRA and the study sponsor, resulting in a minimum age for trial participation of 11 for biological females and 12 for biological males. It is right that this Government, like the previous Government or any Government, are guided by expert clinical and scientific advice and take that approach. The noble Baronesses, Lady Deech and Lady Meyer, asked about eligibility for the PATHWAYS trial, which it tightly controls. It requires individual assent and parental consent—I am glad that the noble Baroness, Lady Deech, referred to the Gillick principle. It also requires a minimum two-year gender incongruence diagnosis, ongoing access to psychosocial support and NHS clinician and multidisciplinary team approval, as well as participant understanding of risks and benefits, physical and mental stability and compliance with safeguarding requirements. I do not consider that to be anything less than a properly considered and evidence-based approach to ensure that we can provide the healthcare that is needed. Questions were raised about parental consent. That is integral. The parent or legal guardian must agree to their child’s involvement. There is no requirement to be a participant, as has been suggested; these people are coming forward. They must also meet the very stringent issues that are put to them. I say to the noble Baroness, Lady Cash, and other noble Lords that children who have gender incongruence deserve to be able to participate in research, as they also deserve evidence-based care, as we all do, in the same way as children with other clinical diagnoses. Masculinising and feminising hormones were referred to in the debate. Following an independent review of evidence, NHS England has launched a consultation which has proposed that these should no longer be available as a routine commissioning option. The outcome of the consultation is under consideration. We will return to that. I conclude by saying that maintaining the safety and well-being of children and young people is our priority and always will be, and I must emphasise that it will always be rooted in evidence.
Lord Winston (Lab)
My Lords—
Baroness Cass (CB)
My Lords—
The Deputy Speaker (Baroness Garden of Frognal) (LD)
My Lords, I regret that the time for this debate has completed—in fact, we are a minute over. I do apologise to noble Lords.
Source: UK Parliament Hansard API. Debate ID: 5423193.